Pay in 4 interest-free payments of $7.06 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Retatrutide is an investigational once-weekly subcutaneous peptide that simultaneously activates GLP-1, GIP, and glucagon receptors to reduce appetite, increase energy expenditure, and promote fat breakdown, though it has not yet received MHRA or EMA authorisation
The full implications for diabetes prescribing will be assessed by NICE if and when retatrutide reaches the UK market
While early evidence is promising, ongoing research will continue to clarify the full extent of Semaglutides benefits in cancer risk reduction
Both begin at the lowest dose, 2.5 mg, once weekly for the first four weeks
US$ 20.33
US$ 27.28
US$ 27.19
US$ 25.15
US$ 28.06
